Biocon Ltd receives approval from SAHPRA for Tacrolimus Capsule

Biocon Limited has received approval from the South African Health Products Regulatory Authority (SAHPRA), for our vertically integrated, complex drug product Tacrolimus capsule 0.5mg, 1mg and 5mg strengths, in South Africa. This is the Company's first approval in this Country.

Tacrolimus, a calcineurin inhibitor, is an immunosuppressant used in the treatment of organ transplant patients, which reduces the body's ability to reject a transplanted organ. It has been particularly effective in treating patients of renal transplant for more than two decades.

Shares of Biocon Limited was last trading in BSE at Rs. 261.70 as compared to the previous close of Rs. 267.30. The total number of shares traded during the day was 346632 in over 5178 trades.

The stock hit an intraday high of Rs. 265.50 and intraday low of 260.00. The net turnover during the day was Rs. 91054156.00.

Source : Equity Bulls

Keywords

Biocon INE376G01013 SAHPRA TacrolimusCapsule